Breakthrough Treatment: Topical Metformin Restores Hair in Severe Alopecia as per new Case study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-07-23 03:15 GMT   |   Update On 2024-07-23 06:48 GMT
Advertisement

Portugal: Central Centrifugal Cicatricial Alopecia (CCCA) presents a challenging condition for dermatologists, often resulting in permanent hair loss among individuals of African descent. Recent studies have explored novel treatments, including topical metformin, demonstrating promising results in halting disease progression and stimulating hair regrowth.

A recent case report published in the International Journal of Dermatology implied that topical metformin 10% compounded cream might be a safe and effective adjunct therapy for patients with CCCA.

Advertisement

A 54-year-old African woman with a history of hypertension was presented to the outpatient department due to significant hair loss affecting the central area of her scalp for the past three years. On examination, alopecia was noted in the vertex region with a negative traction test. Trichoscopy revealed marked perifollicular scaling and whitish-gray perifollicular halos.

Histopathological examination showed concentric laminated fibrosis around pilosebaceous units with sebaceous gland atrophy and moderate lymphocytic inflammatory infiltrate in the dermis, consistent with a diagnosis of central centrifugal cicatricial alopecia in phase 3b. Initially, the patient declined treatment with intralesional corticosteroids and received minoxidil 5% lotion and topical clobetasol 0.05% twice daily, with no improvement after 14 months. Subsequently, the doctors discontinued the topical clobetasol ointment and initiated the once-daily application of topical metformin 10% cream in combination with minoxidil 5% lotion twice daily.

After eight months of treatment, substantial hair regrowth was observed in the vertex region, with new repopulated areas and terminal hair follicles.

"This case report presents findings from a 54-year-old African woman diagnosed with advanced-stage central centrifugal cicatricial alopecia (CCCA), confirmed by histopathology, who experienced persistent hair loss despite initial treatment with topical corticosteroids and minoxidil. Following eight months of daily use of compounded topical metformin 10% cream alongside minoxidil 5% lotion, significant hair regrowth was observed in the vertex area, with no reported adverse effects," Bárbara Vieira Granja, Department of Dermatology and Venereology, Unidade Local de Saúde São João, Porto, Portugal, and colleagues wrote.

"This case report also highlights data from two African American females with advanced-stage central centrifugal cicatricial alopecia who also experienced visible hair regrowth with topical metformin 10% compounded cream."

"The case report underscores the transformative potential of topical metformin 10% cream in managing CCCA, offering hope to patients grappling with this challenging condition. With ongoing research and clinical advancements, dermatologists remain optimistic about refining treatment strategies and improving outcomes for individuals affected by CCCA worldwide," they concluded. 

Reference:

Granja BV, De Matos PR, Rosa GP, Pinheiro J, Azevedo F, Pedrosa AF. Treatment of central centrifugal cicatricial alopecia with topical metformin 10% cream: case report and literature review. Int J Dermatol. 2024 Jun 23. doi: 10.1111/ijd.17345. Epub ahead of print. PMID: 38923417.


Tags:    
Article Source : International Journal of Dermatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News